Business

Hot Stock Overview: Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Share
Aralez focuses on developing cardiovascular disease therapies

In the last Quarter, Aralez Pharmaceuticals Inc.

Southwest Gas Holdings, Inc., formerly Southwest Gas Corporation, is engaged in the business of purchasing, distributing and transporting natural gas. Tiger Legatus Capital Management LLC now owns 1,985,000 shares of the company's stock valued at $8,754,000 after buying an additional 25,000 shares in the last quarter.

Aralez Pharmaceuticals Inc. NASDAQ:ARLZ performance during the last one year Degraded -58.66 percent, while its year to date (YTD) performance showed a Negative trend of -44.22 percent. They expect $-0.34 EPS, up 15.00% or $0.06 from last year's $-0.4 per share. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.11.

The increase in SG&A expenses was primarily driven by increased commercialization costs incurred in the USA, predominantly related to the launch of Yosprala in October 2016, costs to support the build out of the Aralez global corporate structure, continuing operational expenses in Canada, product acquisition-related expenses and higher share based compensation expenses. A total of 1.19 million shares exchanged at hands and its average trading volume is standing at 0.8 million shares. It now has negative earnings. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine.

On 9/15/2016 Robert Paul Harris, Director, sold 150,000 with an average share price of $5.82 per share and the total transaction amounting to $873,000.00. "Outperform View" rating was revealed by 2 and "Underperform Signal" rating was issued by 0.

Ratings analysis reveals 0 of Southwest Gas Corporation's analysts are positive. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

The High Revenue estimate is predicted as 30.5 Million, while the Low Revenue Estimate prediction stands at 30.5 Million. The Price to Sales (P/S) of the stock is 5.76, while P/B (Price to Book) stands at 1.54. The rating was downgraded by Jefferies to "Hold" on Thursday, October 8. The firm earned "Buy" rating on Thursday, November 19 by Canaccord Genuity. The firm presently has a "buy" rating on the stock. The company was upgraded on Thursday, October 13 by Jefferies.

Many research firms have provided their ratings on Aralez Pharmaceuticals Inc. Earnings per share were $-0.4.

Aralez Pharmaceuticals could be a good value at this knocked-down price, but cautious investors will want to wait until management can show that it can consistently grow revenue each quarter before investing. Gamco Investors Inc. Et Al, a New York-based fund reported 946,603 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Share